Entrada Therapeutics (TRDA) News Today → Buy Friday. Sell Monday. (From WealthPress) (Ad) Free TRDA Stock Alerts $14.99 +0.04 (+0.27%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 12:06 AM | finance.yahoo.comDirector Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)May 16 at 7:00 AM | globenewswire.comEntrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 13, 2024 | americanbankingnews.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $31,955.04 in StockMay 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Entrada Therapeutics, Inc. Increased by HC Wainwright (NASDAQ:TRDA)May 12, 2024 | americanbankingnews.comFinancial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Entrada Therapeutics (NASDAQ:TRDA)May 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Acquires $31,955.04 in StockMay 10, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,276 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,276 shares of the business's stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average cost of $14.04 per share, with a total value of $31,955.04. Following the acquisition, the director now directly owns 65,212 shares of the company's stock, valued at approximately $915,576.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 9, 2024 | americanbankingnews.comWilliam Blair Analysts Boost Earnings Estimates for Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 8, 2024 | markets.businessinsider.comEntrada Therapeutics is about to announce earnings — here's what Wall Street expectsMay 8, 2024 | finance.yahoo.comEntrada Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | investorplace.comTRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comEntrada Therapeutics Reports First Quarter 2024 Financial ResultsApril 14, 2024 | nasdaq.comFriday 4/12 Insider Buying Report: ATOS, TRDAApril 12, 2024 | insidermonkey.comInsiders are Piling into These 5 Healthcare Stocks in 2024April 11, 2024 | msn.comInsiders Buying America's Car-Mart And 2 Other StocksApril 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 SharesApril 10, 2024 | marketbeat.comPeter S. Kim Buys 2,600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,600 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the transaction, the director now owns 62,936 shares of the company's stock, valued at approximately $854,041.52. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.April 2, 2024 | insidertrades.comPeter S. Kim Acquires 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockApril 1, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $20,790.00 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 1,512 shares of Entrada Therapeutics stock in a transaction on Thursday, March 28th. The stock was acquired at an average cost of $13.75 per share, for a total transaction of $20,790.00. Following the acquisition, the director now owns 60,336 shares in the company, valued at approximately $829,620. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 27, 2024 | insidertrades.comPeter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMarch 26, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $42,484.80 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 3,180 shares of Entrada Therapeutics stock in a transaction dated Monday, March 25th. The stock was acquired at an average cost of $13.36 per share, with a total value of $42,484.80. Following the completion of the acquisition, the director now owns 56,074 shares of the company's stock, valued at $749,148.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 22, 2024 | insidertrades.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of StockMarch 21, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 900 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 900 shares of the firm's stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $12.66 per share, with a total value of $11,394.00. Following the completion of the transaction, the director now owns 47,944 shares of the company's stock, valued at $606,971.04. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 20, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) to Post Q1 2024 Earnings of ($0.40) Per Share, HC Wainwright ForecastsEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will eaMarch 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 18, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Entrada Therapeutics (NASDAQ:TRDA)HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday.March 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMarch 18, 2024 | marketbeat.comEquities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst M. Minter now forecasts thMarch 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 18, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,990.00 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $15.99, for a total value of $15,990.00. Following the transaction, the chief executive officer now owns 244,279 shares in the company, valued at approximately $3,906,021.21. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.January 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 5, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Now Covered by OppenheimerOppenheimer started coverage on Entrada Therapeutics in a research note on Friday. They issued an "outperform" rating and a $22.00 price target on the stock.January 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?January 3, 2024 | finance.yahoo.comEntrada Therapeutics Promotes Nathan J. Dowden to PresidentDecember 28, 2023 | finance.yahoo.comEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesDecember 26, 2023 | marketbeat.comKory James Wentworth Sells 10,206 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the company's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total transaction of $160,132.14. Following the completion of the sale, the chief financial officer now directly owns 49,571 shares of the company's stock, valued at approximately $777,768.99. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 22, 2023 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 1,000 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $15.00, for a total value of $15,000.00. Following the sale, the chief executive officer now owns 245,279 shares of the company's stock, valued at $3,679,185. The sale was disclosed in a filing with the SEC, which is available through the SEC website.December 20, 2023 | finance.yahoo.comAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAADecember 20, 2023 | finance.yahoo.comRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagDecember 11, 2023 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comPfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EUNovember 29, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDANovember 29, 2023 | finance.yahoo.comImmunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address weirdest stock market marches on (Ad)For the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market” Graham is hosting a “tell all” workshop about his Apex Indicator here TRDA Media Mentions By Week TRDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼1.020.50▲Average Medical News Sentiment TRDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼91▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adlai Nortye News Lexicon Pharmaceuticals News Acelyrin News Oculis News Corbus Pharmaceuticals News Fulcrum Therapeutics News Theravance Biopharma News Larimar Therapeutics News PepGen News Travere Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
